Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 66.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,770 shares of the biopharmaceutical company’s stock after purchasing an additional 1,902 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $1,122,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Allworth Financial LP lifted its stake in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 38 shares during the period. Nixon Peabody Trust Co. lifted its stake in shares of Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after purchasing an additional 43 shares during the period. Brevan Howard Capital Management LP lifted its stake in shares of Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 44 shares during the period. IFP Advisors Inc lifted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 47 shares during the period. Finally, Nwam LLC lifted its stake in shares of Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ALNY. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a report on Friday, March 21st. Finally, Royal Bank of Canada raised their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $319.17.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $289.00 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39. The firm has a 50 day moving average price of $257.45 and a 200 day moving average price of $254.27. The company has a market cap of $37.68 billion, a price-to-earnings ratio of -133.18 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts’ expectations of $584.32 million. During the same period last year, the firm posted ($0.16) EPS. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.